City

Clinical trials near Wuhan, China

Active studies with a listed research site in Wuhan, China.

21active studies

10recruiting now

15countries represented

136largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Knee Osteoarthritis, ObesityCondition

Ecnoglutide Injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07734311See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

Overweight and ObesityCondition

HRS9531 injection；Placebo, HRS9531 injection；PlaceboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-31 · NCT07559136See eligibility →

Recruiting nowPhase 1

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Adolescence ObesityCondition

Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QWTreatment

China5 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-07-30 · NCT07693426See eligibility →

Recruiting nowNot applicable

Real-World Case Registry Study on Obesity

Obesity & Overweight, Obesity (Disorder)Condition

Intervention not listedTreatment

China1 locations

Hubei Hospital of Traditional Chinese MedicineSponsor

Updated 2026-06-12 · NCT07448090See eligibility →

Recruiting nowNot applicable

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Obesity, Weight ControlCondition

Mazdutide, Intensive Lifestyle InterventionTreatment

China13 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-04-08 · NCT07517042See eligibility →

Recruiting nowNot applicable

A Study on Application of Adjustable Headrest in Painless Curettage Surgery for Overweight and Obese Patients

Adjustable Headrests, Ventilation FunctionCondition

the supine head-lateral position group, the adjustable headrest groupTreatment

China1 locations

Maternal and Child Health Hospital of Hubei ProvinceSponsor

Updated 2025-04-15 · NCT06929000See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonNot applicable

Efficacy of Mazdutide on Fatty Pancreas

Fatty Pancreas, OverweightCondition

mazdutide, Placebo matching mazdutideTreatment

China1 locations

Tongji HospitalSponsor

Updated 2026-09-04 · NCT07803705See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

Overweight/ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China10 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07798284See eligibility →

Opening soonPhase 2

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

Obesity, OverweightCondition

Mazdutide(Dual GLP-1R/GCGR Agonist), PlaceboTreatment

China6 locations

Tongji HospitalSponsor

Updated 2026-08-24 · NCT07781150See eligibility →

Opening soonNot applicable

Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

Obesity & OverweightCondition

inulin (prebiotics), Placebo Comparator: maltodextrinTreatment

China5 locations

Huazhong University of Science and TechnologySponsor

Updated 2026-06-03 · NCT07611552See eligibility →

Opening soonPhase 4

AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

Overweight or Obesity; Type 2 Diabetes, Weight Loss MaintenanceCondition

AI assisted multi-domain lifestyle intervention, TirzepatideTreatment

China1 locations

Huazhong University of Science and TechnologySponsor

Updated 2026-04-29 · NCT07555730See eligibility →

Opening soonPhase 4

Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients

Psoriasis, Plaque PsoriasisCondition

Secukinumab 300mg s.c., MetforminTreatment

China1 locations

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySponsor

Updated 2026-03-25 · NCT07485764See eligibility →

Opening soonPhase 3

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

Overweight or ObesityCondition

MDR-001, PlaceboTreatment

China45 locations

MindRank AI LtdSponsor

Updated 2025-12-22 · NCT07274137See eligibility →

Opening soonNot applicable

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

Severe ObesityCondition

Sleeve gastrectomy plus early mazdutide initiation, Sleeve gastrectomy followed with early mazdutide placebo initationTreatment

China14 locations

Beijing Friendship HospitalSponsor

Updated 2025-08-21 · NCT07135141See eligibility →

Active, not recruitingPhase 3

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

Overweight , ObesityCondition

Zovaglutide dose 1, Zovaglutide dose 2Treatment

China45 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-08-03 · NCT07230119See eligibility →

Active, not recruitingPhase 2, Phase 3

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Obesity and OverweightCondition

Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QWTreatment

China41 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-01-30 · NCT06921486See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Wuhan, China

Current studies

Related cities